Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)

European Archives of Psychiatry and Clinical Neuroscience

Volumn 262, Issue 2, 2012, Pages 139-149

  Cordon, Rosario De Arce ^a   Eding, Evelin ^b   Marques Teixeira, Joao ^c   Milanova, Vihra ^d   Rancans, Elmars ^e   Schreiner, Andreas ^f  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b North Estonian Regional Hospital   (Estonia)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^e RIGA STRADINS UNIVERSITY   (Latvia)

^f JANSSEN CILAG GMBH   (Germany)

Author keywords

Antipsychotic; Atypical; Relapse; Schizoaffective disorder schizophrenia

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DELIRIUM; DELUSION; DESCRIPTIVE RESEARCH; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERKINESIA; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREMOR; VITAL SIGN; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; RECURRENCE; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS;

EID: 84863009496     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-011-0220-8     Document Type: Article

References (31)

1. Schooler NR (2006) Relapse prevention and recovery in the treatment of schizophrenia. J Clin Psychiatry 67 (suppl 5):19-23 (Pubitemid 43837698)
2. Altamura AC, Bobo WV, Meltzer HY (2007) Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol 22:249-267 (Pubitemid 47237544)
3. Rosa MA, Marcolin MA, Elkis H (2005) Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia. Rev Bras Psiquiatr 27:178-184 (Pubitemid 41337480)
4. Leucht S, Heres S (2006) Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67 (suppl 5):3-8 (Pubitemid 43837695)
5. Cassano GB, Fagiolini A, Lattanzi L, Monteleone P, Niolu C, Sacchetti E, Siracusano A, Vita A (2007) Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clin Drug Investig 27:1-13 (Pubitemid 46058731)
6. Limosin F, Azorin JM, Krebs MO, Millet B, Glikman J, Camus V, Crocq MA, Costentin J, Daléry J (2008) Present data and treatment schedule of aripiprazole in the treatment of schizophrenia. Encephale 34:82-92
7. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41
8. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159:103-108 (Pubitemid 41070734)
9. Kane JM (2007) Treatment adherence and long-term outcomes. CNS Spectr 12 (suppl 17):21-26 (Pubitemid 350099581)
10. Linden M, Godemann F (2007) The differentiation between ''lack of insight'' and ''dysfunctional health beliefs'' in schizophrenia. Psychopathology 40:236-241 (Pubitemid 46717838)
11. Löffler W, Kilian R, Toumi M, Angermeyer MC (2003) Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 36:105-112 (Pubitemid 36791785)
12. Yamada K, Watanabe K, Nemoto N, Fujita H, Chikaraishi C, Yamauchi K, Yagi G, Asai M, Kanba S (2006) Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Psychiatry Res 141:61-69 (Pubitemid 43011351)
13. Kane JM (2006) Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 67 (suppl 5):9-14 (Pubitemid 43837696)
14. Schooler NR (2003) Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 64 (suppl 16):14-17 (Pubitemid 37523323)
15. Lasser RA, Bossie CA, Gharabawi GM, Kane JM (2005) Remission in schizophrenia: Results from a 1-year study of longacting risperidone injection. Schizophr Res 77:215-227 (Pubitemid 41112215)
16. Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, Eriksson L, Smeraldi E (2010) Relapse prevention in schizophrenia and schizoaffective disorder with risperidone longacting injectable versus quetiapine: results of a long-term, openlabel, randomized clinical trial. Neuropsychopharmacology 35:2367-2377
17. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
18. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16-22 (Pubitemid 34438915)
19. Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538-546 (Pubitemid 28100274)
20. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441-449 (Pubitemid 40343909)
21. Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, Llorca PM (2005) Direct transition to long-acting risperidone-analysis of long-term efficacy. J Psychopharmacol 19 (suppl):15-21 (Pubitemid 41392293)
22. Macfadden W, Ma YW, Thomas Haskins J, Bossie CA, Alphs L (2010) A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont) 7 (11):23-31
23. Ware J Jr, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220-233 (Pubitemid 126433231)
24. Martin CR, Allan R (2007) Factor structure of the Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4). Psychol Health Med 12:126-134
25. Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980) Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 7:233
26. Gharabawi GM, Gearhart NC, Lasser RA, Mahmoud RA, Zhu Y, Mannaert E, Naessens I, Bossie CA, Kujawa M, Simpson GM (2007) Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry 6:3
27. Moeller KE, Shireman TI, Liskow BI (2006) Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. J Clin Psychiatry 67:1942-1947 (Pubitemid 46048192)
28. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG, Aripiprazole Study Group (2003) Aripirazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin vPsychiatry 64:1048-1056 (Pubitemid 37158250)
29. Bai YM, Chen TT, Wu B (2006) A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 39:135-141 (Pubitemid 44199181)
30. Komossa K, Rummel-Kluge C, Schmid F et al (2010) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev CD006625
31. Komossa K, Rummel-Kluge C, Schmid F et al (2009) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev CD006569